Company Overview
Company Type: Public Company
Company Status: Operating Subsidiary
Website: www.medmira.com
Number of Employees: 52
Ticker: MIR (TSXV)
Year Founded: 1993


Business Description
MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, the Asia Pacific, and internationally. The company offers Reveal HIV that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests, including combination testing solutions for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product to perform preliminary screening of HIV and hepatitis. It also provides Miriad RVF toolkit that facilitates the development and commercialization of rapid diagnostics; and Reveal HP, a rapid H. Pylori antibody test, which detects helicobacter pylori (HP) antibodies in serum, plasma, or whole blood produced in response to HP infection. In addition, the company offers VYRA CoV2 that detects antigens specific for the nucleocapsid region of SARS-CoV-2; VYRA CoV2Flu, a combination viral nucleocapsid antigen tests that detects infection caused by SARS-CoV-2, and Influenza A and Influenza B; and REVEALCOVID-19, an antibody test. It sells its products through a network of medical distributors and strategic business development partners to customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.

Financial Information (Currency: CAD, in mm) 
Total Revenue
0.5
Market Capitalization
59.3
TEV/Total Revenue
131.3x
EBITDA
(1.9)
Total Enterprise Value
69.0
TEV/EBITDA
NM
EBIT
(1.9)
Cash & ST Invst.
0.1
P/Diluted EPS Before Extra
NM
Net Income
(2.2)
Total Debt
9.8
Price/Tang BV
NM
Capital Expenditure
(0.1)
Total Assets
3.8
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Apr-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023

Key Professionals
Name
Title
Chan, Hermes 
Co-Founder, CEO, President & Director
Meile, Markus M.
Chief Financial Officer
Ratnam, Sam 
Director of Scientific & Regulatory Affairs
McKelvey, Stewart
Legal Counsel
Jones, Kevin D.
Head of Commercialization and Senior Director of Sales & Marketing

Key Board Members
Name
Title
Bergmann, Thomas 
Independent Chairman
Chan, Hermes 
Co-Founder, CEO, President & Director
Cummings, Steven 
Independent Director
Mao, Jianhe 
Independent Director
Nini, Pascale 
Independent Director


Primary Industry Classification
Health Care Equipment


Primary Office Location
155 Chain Lake Drive Suite 1 | Halifax, NS | B3S 1B3 | Canada
Fax: 877 633 6372

Parent Company
MedMira Holding AG

Current and Pending Investors
American Health Diagnostics, LLC, Andurja AG, Morningside Venture IV Investments Limited, The Morningside Group Limited

Prior Investors
make a startup GmbH, Redalpine Venture Partners AG, YA Global Investments, L.P., Yorkville Advisors Global LP

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.09
Market Cap (mm)
62.8
Open
 0.09
Shares Out. (mm)
697.4
Previous Close
 0.09
Float %
-
Change on Day
0.0050
Shares Sold Short (mm)
-
Change % on Day
5.9%
Dividend Yield %
-
Day High/Low
 0.09/ 0.09
Diluted EPS Excl. Extra Items
0.00
52 wk High/Low
 0.17/ 0.05
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0010
Avg 3M Dly Vlm (mm)
0.07
Beta 5Y
10.58


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)
TSXV:MIR - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
SensorChem International Corporation
Biosensor products for multiple markets including drug discovery, clinical diagnostics, toxicology & environmental monitoring As of February 23, 2006, SensorChem International Corporation operates as a subsidiary of MedMira Inc.

United States and Canada
Biotechnology
-
-
-
MedMira Inc.
In March 2000, MedMira, Inc. acquired MedMira Laboratories, Inc. in a transaction that was treated for accounting purposes as an acquisition of MedMira by MedMira Laboratories. Previously, MedMira, Inc. did not have any significant operations.

United States and Canada
Health Care Equipment
-
-
-
Precious Lfie Saving Products Inc.

United States and Canada
-
-
-
-
Seneca Equities Corp.
Seneca Equities Corp. operates as a subsidiary of MedMira Inc.

United States and Canada
-
-
0.00
0.00


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Dec-14-2021
Dec-14-2021
Private Placement
Target
MedMira Inc. (TSXV:MIR)
MedMira Holding AG

1.30
Jul-15-2021
Jul-15-2021
Private Placement
Target
MedMira Inc. (TSXV:MIR)


0.40
Sep-02-2015
Sep-08-2015
Private Placement
Target
MedMira Inc. (TSXV:MIR)
Onsite Lab Holding AG

3.79
Mar-25-2015
Mar-27-2015
Private Placement
Target
MedMira Inc. (TSXV:MIR)
Onsite Lab Holding AG

0.87
Sep-30-2014
Sep-30-2014
Private Placement
Target
MedMira Inc. (TSXV:MIR)


0.99
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-28-2023
Product-Related Announcements
Medmira Inc. Provides Update on Its Progress to Achieve Regulatory Approval in Canada and the USA for Its Infectious Disease Rapid Tests
Mar-14-2023
Product-Related Announcements
MedMira Inc. Provides an Update on Its Progress to Achieve Regulatory Approval in Canada for Its Reveal TP (Syphilis) Antibody Test
Feb-20-2023
Client Announcements
Maternova and MedMira Enter Distribution Agreement to Market Rapid Diagnostics for HIV, Syphilis and Hepatitis
Feb-16-2023
Annual General Meeting
MedMira Inc., Annual General Meeting, Feb 16, 2023
Dec-30-2022
Product-Related Announcements
MedMira Inc. Introduces VYRA TriDemic

Competitors
Alere Inc., OraSure Technologies, Inc. (NasdaqGS:OSUR), Trinity Biotech plc (NasdaqGS:TRIB)


Advisors
Most Recent Auditor
Arsenault Best Cameron Ellis
Private Placement Advisors
Channel Financial Group, Loewen Ondaatje McCutcheon Limited, Investment Banking Arm, Octagon Capital Corporation
Key development Advisor
Alira Health Transaction Services, LLC


Most Recent Auditor
ArsenaultBestCameronEllis


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

03:21 AM
MIR
MedMira Inc 2023_10_05
Reports
14
GlobalData

Sep 14, 2023 11:14 PM
MIR
MedMira Inc (MIR.CVE) - Medical Devices Product Pipeline Summary
Reports
47
GlobalData

Sep 11, 2023 11:01 PM
MIR
MedMira Inc (MIR.CVE) - Financial Analysis Review
Reports
182
S&P Global Compustat

Sep 07, 2023 03:06 AM
MIR
MedMira Inc 2023_09_07
Reports
14
S&P Global Compustat

Jul 06, 2023 02:45 AM
MIR
MedMira Inc 2023_07_06
Reports
14
GlobalData

Jun 14, 2023 01:23 AM
MIR
MedMira Inc (MIR.CVE) - Financial Analysis Review
Reports
184
GlobalData

Jun 09, 2023 07:03 AM
MIR
MedMira Inc (MIR.CVE) - Medical Devices Product Pipeline Summary
Reports
46
S&P Global Compustat

Jun 01, 2023 03:15 AM
MIR
MedMira Inc 2023_06_01
Reports
14
Wright Investors' Service Inc.

May 24, 2023 01:41 AM
MIR
Flow of Funds Report for Medmira Inc. - prepared by Wright Investors Service
Notes
69
S&P Global Compustat

May 04, 2023 02:59 AM
MIR
MedMira Inc 2023_05_04
Reports
14



Top Buyers
No Top Buyers data available.

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Onsite Lab Holding AG
0
(494,199,013)
Chan, Hermes 
0
(2,908,633)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Consulting Services, Contract Research Services, MedMira Rapid H. Pylori Antibody Test, MedMira Rapid H. Pylori Confirmatory Test (Future), MedMira Rapid Influenza A&B Test (Future), MedMira Rapid Vertical Flow Technology Platform, MiraWell Digital Rapid Reader, MiraWell HIV Prevention Program, MiraWell Rapid H. Pylori Test, Miriad RVF Toolkit, Multiplo HBc/HIV/HCV Tests, Multiplo HIV Rapid Test, Multiplo HIV/HCV Test, Multiplo TP/HIV rapid test, Product Conversion Services, Rapid Diagnostic Products and Services, Reveal G3 Rapid HIV-1 Antibody Test, Reveal G4 Point-of-care Test, Reveal G4 Rapid HIV-1 Antibody Test, Reveal HBsAg Tests (Future), Reveal HIV antibody test, Reveal TP Antibody Test (Future), REVEALCOVID-19 PLUS Total Antibody Test (Future), VYRA TriDemic Antigen Rapid Test


Upcoming Events
Date/Time
Type
Oct-11-2023
Estimated Earnings Release Date (S&P Global Derived)
Nov-29-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Jun-29-2023
-
MedMira Inc. (TSXV:MIR)
SEDAR
News Releases
196 KB
Jun-29-2023
Apr-30-2023
MedMira Inc. (TSXV:MIR)
SEDAR
Interim Financial Statements
362 KB
Apr-03-2023
-
MedMira Inc. (TSXV:MIR)
SEDAR
News Releases
45 KB
Apr-03-2023
Jan-31-2023
MedMira Inc. (TSXV:MIR)
SEDAR
Interim Financial Statements
358 KB
Mar-14-2023
-
MedMira Inc. (TSXV:MIR)
SEDAR
News Releases
101 KB
Feb-20-2023
-
MedMira Inc. (TSXV:MIR)
SEDAR
News Releases
61 KB
Jan-24-2023
-
MedMira Inc. (TSXV:MIR)
SEDAR
Management Proxy Materials
71 KB
Jan-24-2023
-
MedMira Inc. (TSXV:MIR)
SEDAR
Management Proxy Materials
88 KB
Jan-24-2023
-
MedMira Inc. (TSXV:MIR)
SEDAR
Management Proxy Materials
360 KB
Jan-24-2023
-
MedMira Inc. (TSXV:MIR)
SEDAR
Management Proxy Materials
235 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Chan, Hermes  (Co-Founder, CEO, President & Director)
Mar-22-2021
Common Shares
300,000
32,912
Derivative Exercise and Retained Stock
11.50
Exchange Announcement
Robar, Marvyn  (Former Non-Executive Chairman)
Aug-27-2014
Common Shares
46,000
3,771
Open Market Acquisition
New
Exchange Announcement
Meile, Markus M. (Chief Financial Officer)
Oct-18-2013
Common Shares
155,000
9,321
Private Acquisition
0.04
Ownership News/Research
Meile, Markus M. (Chief Financial Officer)
Oct-15-2013 - Oct-16-2013
Common Shares
72,000
4,295
Private Acquisition
0.02
Ownership News/Research
-
Oct-15-2013
Common Shares
44,000
2,623
Private Acquisition
-
Ownership News/Research
-
Oct-16-2013
Common Shares
28,000
1,672
Private Acquisition
-
Ownership News/Research
Meile, Markus M. (Chief Financial Officer)
Sep-30-2013 - Oct-01-2013
Common Shares
122,200,000
8,159,065
Private Acquisition
52.53
Ownership News/Research
-
Sep-30-2013
Common Shares
122,100,000
8,152,418
Private Acquisition
-
Ownership News/Research
-
Oct-01-2013
Common Shares
100,000
6,647
Private Acquisition
-
Ownership News/Research
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Bergmann, Thomas 
Independent Chairman
(647) 670-2882
877 633 6372

Chan, Hermes 
Co-Founder, CEO, President & Director
-
877 633 6372

Cummings, Steven 
Independent Director
-
877 633 6372

Mao, Jianhe 
Independent Director
-
877 633 6372

Nini, Pascale 
Independent Director
-
877 633 6372

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Chan, Hermes 
Co-Founder, CEO, President & Director
-
877 633 6372

Meile, Markus M.
Chief Financial Officer
902-450-1588
877 633 6372
m.meile@medmira.com
Ratnam, Sam 
Director of Scientific & Regulatory Affairs
-
877 633 6372

McKelvey, Stewart
Legal Counsel
-
877 633 6372
-
Jones, Kevin D.
Head of Commercialization and Senior Director of Sales & Marketing
-
877 633 6372
-
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
